Value
9.0/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.9 |
| Fwd P/E | 10.0 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 5.2x
- ▸PEG: 0.03
- ▸Attractively valued
VALN · Why this verdict
Why Valneva (VALN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock trades at a deeply discounted valuation (forward P/E of 5.0x, PEG of 0.03) with an extreme asymmetry ratio of 12.53 and 98.5% upside to its take-profit target against just 6.4% downside to its stop-loss. Targets | The stock should advance materially toward its $10.37 take-profit target without breaching the $4.89 stop-loss over the next 12 months. | →Stable |
| CounterA quality score below the engine's floor and declining revenue suggest the deep discount may reflect fundamental deterioration rather than a mispriced opportunity. | ||
The stock's quality score of 1.6 sits well below the engine's 4.0 minimum floor, triggering an exit recommendation, with cash burn at -20% of revenue and a weak Piotroski F-Score of 3 out of 9. Quality breakdown | The quality score should climb back above the 4.0 floor and free cash flow should turn less negative over the next 12 months. | →Stable |
| CounterAs a vaccine-focused biotech, near-term cash burn tied to R&D investment can be a normal feature of the business model rather than a sign of distress. | ||
Revenue is declining 37% year-over-year, a sharp contraction that raises questions about near-term demand for the company's products. Growth breakdown | Revenue growth should turn positive over the next 4 quarters to reverse the current contraction. | →Stable |
| CounterVaccine-sector revenue can be highly lumpy due to large government or bulk-order contracts, so a single-period decline may not indicate a structural demand problem. | ||
The stock is in a confirmed technical downtrend (below its 200-day moving average with a -6.6%/30d slope) and has triggered a hard-blocking death cross gate, though the engine notes MACD is improving alongside an RSI of 46. Engine gate (failed) | The stock should reclaim its 200-day moving average and the death-cross block should clear over the next 2 quarters for the recovery setup to be validated. | →Stable |
| CounterFalling on-balance volume signals continued distribution, which could mean the downtrend deepens rather than resolves into a recovery. | ||
At a $0.5 billion market cap, the stock sits below the reach of many institutional investors, an edge the engine flags that can leave shares under-owned and mispriced relative to fundamentals. Edge rationale | As market cap grows or institutional ownership increases over the next 12 months, this constraint-driven mispricing edge should narrow as the price adjusts. | →Stable |
| CounterBeing below institutional reach can just as easily reflect elevated leverage risk (debt-to-equity of 8.5) and volatility rather than a genuine mispricing opportunity. | ||
The stock trades at a deeply discounted valuation (forward P/E of 5.0x, PEG of 0.03) with an extreme asymmetry ratio of 12.53 and 98.5% upside to its take-profit target against just 6.4% downside to its stop-loss.
→StableTargets
- Expectation
- The stock should advance materially toward its $10.37 take-profit target without breaching the $4.89 stop-loss over the next 12 months.
CounterA quality score below the engine's floor and declining revenue suggest the deep discount may reflect fundamental deterioration rather than a mispriced opportunity.
The stock's quality score of 1.6 sits well below the engine's 4.0 minimum floor, triggering an exit recommendation, with cash burn at -20% of revenue and a weak Piotroski F-Score of 3 out of 9.
→StableQuality breakdown
- Expectation
- The quality score should climb back above the 4.0 floor and free cash flow should turn less negative over the next 12 months.
CounterAs a vaccine-focused biotech, near-term cash burn tied to R&D investment can be a normal feature of the business model rather than a sign of distress.
Revenue is declining 37% year-over-year, a sharp contraction that raises questions about near-term demand for the company's products.
→StableGrowth breakdown
- Expectation
- Revenue growth should turn positive over the next 4 quarters to reverse the current contraction.
CounterVaccine-sector revenue can be highly lumpy due to large government or bulk-order contracts, so a single-period decline may not indicate a structural demand problem.
The stock is in a confirmed technical downtrend (below its 200-day moving average with a -6.6%/30d slope) and has triggered a hard-blocking death cross gate, though the engine notes MACD is improving alongside an RSI of 46.
→StableEngine gate (failed)
- Expectation
- The stock should reclaim its 200-day moving average and the death-cross block should clear over the next 2 quarters for the recovery setup to be validated.
CounterFalling on-balance volume signals continued distribution, which could mean the downtrend deepens rather than resolves into a recovery.
At a $0.5 billion market cap, the stock sits below the reach of many institutional investors, an edge the engine flags that can leave shares under-owned and mispriced relative to fundamentals.
→StableEdge rationale
- Expectation
- As market cap grows or institutional ownership increases over the next 12 months, this constraint-driven mispricing edge should narrow as the price adjusts.
CounterBeing below institutional reach can just as easily reflect elevated leverage risk (debt-to-equity of 8.5) and volatility rather than a genuine mispricing opportunity.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Valneva shows an extreme risk/reward asymmetry (12.53x, 98.5% upside) at a deeply discounted valuation and small-cap institutional-constraint edge, but a quality score below the engine's floor, declining revenue, and a confirmed technical downtrend with a hard death-cross block argue the discount reflects real fundamental weakness.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.4 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -20% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 10.0 |
- ▸Declining revenue: -37%
Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.6 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.8 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.0%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 130%
Insider
5.0/10data confidence 50%Peer rank
2.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 0.3 |
| growth rank | 2.2 |
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 4.6 |
| 52w position | 0.0 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.9 |
| days to cover | 5.5 |
| volatility | 2.7 |
| beta | 5.3 |
| debt equity | 2.3 |
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:5.2>=4.5
- ASYMMETRY:12.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:37d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- DEATH_CROSS:momentum=5.2>=5.0 recovering
Reward-to-Risk
12.09
Upside
+95.3%
Downside
7.9%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 48
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Drawdown -57% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 6.6, and Momentum at 5.2; the weakest are Quality at 1.6, Catalyst at 2.5, and Peer rank at 2.9. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 12.09 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Value Extreme Asymmetry
Trip ifStock price falls below the $4.89 stop-loss, a decline of more than 6% from the current $5.225.
- P2Quality Floor Breach Cash Burn
Trip ifQuality score rises above 4.0 from the current 1.6.
- P3Declining Revenue Growth Concern
Trip ifRevenue growth rises above 0% YoY for 2 consecutive quarters.
- P4Confirmed Downtrend Death Cross
Trip if200-day moving average slope turns positive, rising above 0%/30d from the current -6.6%/30d.
- P5Institutional Constraint Small Cap Edge
Trip ifMarket capitalization rises above $2 billion from the current $0.5 billion.